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Abstract
Introduction: Self-Help Plus (SH+) is a group-based psycho-
logical intervention developed by the World Health Organi-
zation for managing stress. Objective: To assess the effec-
tiveness of SH+ in preventing mental disorders in refugees 
and asylum seekers in Western Europe. Methods: We con-
ducted a randomized controlled trial in 5 European coun-
tries. Refugees and asylum seekers with psychological dis-
tress (General Health Questionnaire score ≥3), but without a 
Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM-5) or ICD/10 diagnosis of mental disorder, as 
assessed with the Mini International Neuropsychiatric Inter-
view (MINI), were randomized to SH+ or enhanced treat-
ment as usual (ETAU). The primary outcome was the fre-
quency of mental disorders with the MINI at 6 months. Sec-
M. von Ommeren and C. Barbui contributed equally to this study.
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-
mercial purposes requires written permission.
Purgato et al.Psychother Psychosom2
DOI: 10.1159/000517504
ondary outcomes included the frequency of mental disorders 
at postintervention, self-identified problems, psychological 
symptoms, and other outcomes. Results: Four hundred fifty-
nine individuals were randomly assigned to SH+ or ETAU. For 
the primary outcome, we found no difference in the frequen-
cy of mental disorders at 6 months (Cramer V = 0.007, p = 
0.90, RR = 0.96; 95% CI 0.52–1.78), while the difference sig-
nificantly favored SH+ at after the intervention (secondary 
outcome, measured within 2 weeks from the last session; 
Cramer V = 0.13, p = 0.01, RR = 0.50; 95% CI 0.29–0.87). Con-
clusions: This is the first randomized indicated prevention 
study with the aim of preventing the onset of mental disor-
ders in asylum seekers and refugees in Western Europe. As a 
prevention effect of SH+ was not observed at 6 months, but 
rather after the intervention only, modalities to maintain its 
beneficial effect in the long term need to be identified.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Refugees and asylum seekers are at an elevated risk of 
developing psychological symptoms and mental disor-
ders in association with the numerous challenges that 
they experience before, during, and after migration [1–7]. 
In response to such challenges, a growing body of re-
search has demonstrated the effectiveness of mental 
health interventions in treating psychological symptoms 
experienced by refugees and asylum seekers [8–16]. How-
ever, in relation to prevention, a recent Cochrane system-
atic review identified only 7 randomized controlled trials 
(RCT) examining the preventive effects of psychosocial 
interventions in humanitarian settings [15]. Of these, 
many did not systematically exclude participants with a 
probable mental disorder at baseline, and most did not 
assess for the development of a probable mental disorder 
at follow-up. Indeed, the review found no studies that 
evaluated incidence, and no overall preventive effects 
were identified for other outcomes such as symptom re-
duction or functioning [15]. 
The World Health Organization (WHO) has devel-
oped a novel, low-intensity, 5-session, group-delivered, 
guided self-help intervention for managing stress and 
coping with adversity. It is designed to be delivered by 
nonspecialist facilitators and does not require extensive 
training [17]. This psychological intervention, called Self-
Help Plus (SH+), is intended to help people cope with 
distress stemming from diverse types of adversity and to 
enhance psychological flexibility [17]. SH+ was recently 
tested in a large cluster RCT with the aim of reducing psy-
chological distress and improving functioning at a 
3-month follow-up in a group of 694 severely distressed 
South Sudanese female refugees in Uganda [18]. In com-
parison with enhanced treatment as usual (ETAU), SH+ 
led to a significant reduction in psychological distress im-
mediately after the intervention (ß = –3.25; 95% CI –4.31 
to –2.19, p < 0.0001, d = –0.72) and at the 3-month follow-
up (ß = –1.20; 95% CI –2.33 to –0.08, p = 0.04, d = –0.26). 
The easily implementable structure of SH+, its con-
tents, and its delivery modality may make this interven-
tion a potentially useful public health strategy for pre-
venting mental disorders in refugees and asylum seekers 
living in high-income countries. We therefore evaluated 
SH+ as an indicated preventive intervention for reducing 
the frequency of current mental disorders at a 6-month 
follow-up in refugees and asylum seekers experiencing 
psychological distress, but without mental disorders, as 
compared with ETAU. We additionally tested SH+ on a 
broader range of secondary outcomes, including psycho-
logical symptoms, functioning, wellbeing, perceived psy-




We conducted a rater-blind, parallel group, multinational RCT 
in 5 countries (Italy, Germany, Austria, Finland, and 2 sites in the 
UK, i.e., 1 in England and 1 in Scotland). The trial protocol was 
registered in clinicaltrials.gov (NCT03571347) before the start of 
recruitment and submitted and published in a scientific journal 
after the start of recruitment [19]. No changes were made to the 
study design after the start of the trial. An individual level random-
ization was chosen because of potential heterogeneity across clus-
ters located in different European countries.
Participant recruitment occurred from September 1, 2018, to 
November 30, 2019. Project coordinators at each site approached 
local organizations providing social, health, and/or legal support 
to refugees and asylum seekers to identify potentially eligible par-
ticipants. Based on a situational analysis of international migration 
flows, we identified refugees and asylum seekers from Syria, Af-
ghanistan, Pakistan, Iraq, and Nigeria as potential target groups. 
All screening, baseline, and follow-up assessment questionnaires 
were administered in interview format or self-administered after 
the participants signed informed consent forms. Assessors were 
healthcare professionals who were trained in the administration of 
rating scales, instructed on how to perform follow-up assessments 
while preserving effective masking, and assisted by cultural me-
diators when needed. 
Randomization and Masking
Randomization was centralized and coordinated by the WHO 
Collaborating Centre of the University of Verona. The randomiza-
tion schedule was generated by the electronic software Castor Elec-
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tronic Data Capture (EDC) [20], employing a variable block ran-
domization method (block sizes: 4 and 6). Research team members 
involved in recruitment were able to access the web-based software 
to randomize each newly enrolled participant, but they were not 
able to access the randomization list and they were not aware of 
the block size. Castor EDC software allowed random allocation 
only after the main information on the enrolled participant had 
been entered, upon verification of the inclusion criteria. After ran-
dom allocation, the software produced a unique identification 
number (ID) for each participant.
Masking of participants and research staff was not feasible due 
to the nature of the intervention. However, assessors evaluating 
primary and secondary outcomes, and the statistician performing 
the analyses, were masked to the participant allocation status. The 
trial statistician was not involved in determining the participants’ 
eligibility, in administering the intervention, in measuring the out-
comes, or in entering data. 
Inclusion and Exclusion Criteria
Refugees and asylum seekers at 1 of the 6 sites of the 5 Euro-
pean countries who presented psychological distress as assessed by 
the 12-item General Health Questionnaire (GHQ ≥3) [21] but did 
not meet the criteria for a mental disorder according to the Mini 
International Neuropsychiatric Interview (MINI) [22] were eligi-
ble to be randomly assigned to SH+ or ETAU in a 1:1 ratio. The 
MINI was designed as a brief structured interview for the diagno-
sis of current mental disorders in the Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM-5) [23] and the 
ICD-10 classification of mental and behavioral disorders [24]. Par-
ticipants were excluded if they: (1) had a mental disorder accord-
ing to the MINI [22]; (2) had an acute medical condition contra-
indicating study participation; (3) presented clinical evidence of an 
imminent suicide risk or a suicide risk scored as “moderate or 
high” (or a suicidality disorder according to the MINI suicidality 
module); (4) were not able to understand Dari, Urdu, Arabic, or 
English; or (5) showed signs of impaired decision-making as evi-
denced by responses during the clinical interview. Refugees and 
asylum seekers who were excluded because of a diagnosis of a men-
tal disorder and/or an imminent suicide risk were referred to pro-
fessional treatment. 
Experimental and Control Intervention
The intervention delivery period lasted from September 2018 
until March 2020. The SH+ program was developed by the WHO, 
as described elsewhere [17]. SH+ consists of a prerecorded audio 
course delivered by briefly trained facilitators in a group setting 
and complemented with an illustrated self-help book adapted for 
the cultural groups included in the study. It was recently updated 
and published by the WHO as Doing What Matters in Times of 
Stress: An Illustrated Guide [25]. 
The prerecorded audio format of SH+ is innovative in that it 
seeks to ensure that key intervention components are delivered as 
intended without the burden of extensive facilitator training. The 
SH+ program is based on acceptance and commitment therapy 
(ACT), a form of cognitive-behavioral therapy [26]. ACT empha-
sizes learning new ways to accommodate difficult thoughts and 
feelings while guiding people to take proactive steps toward living 
in a way that is consistent with their values [17]. 
The SH+ prerecorded audio material is delivered across five 
2-h sessions to groups of up to 30 people. The audio material im-
parts key information about stress management and guides par-
ticipants through individual exercises and small-group discus-
sions. To augment the audio recordings, an illustrated self-help 
book reviews all essential content and concepts. 
The SH+ intervention was fully delivered in the native language 
of the participants by trained facilitators with a migration back-
ground, who were native speakers of the target languages and pro-
ficient in English. Most facilitators had no prior work experience 
in this field and/or formal mental health training. Facilitators com-
pleted 5 days of training, which included listening to the audio 
recordings, receiving instruction on SH+ facilitation skills, and 
role-playing and practicing SH+ sessions. The facilitator’s role 
consisted of playing the audio, responding to questions and dis-
ruptions, demonstrating the exercises, and reading out scripted 
discussion questions. 
Intervention supervision was provided by clinical psycholo-
gists or other health care professionals, who were also available for 
questions, discussion, and debriefing after the sessions. If neces-
sary, additional training and consultations were available from 
SH+ expert trainers at the WHO through local visits. Fidelity was 
checked by the intervention supervisor through session adherence 
forms completed by the facilitators. In addition, the intervention 
supervisor (a clinical psychologist, a psychiatrist, or a specialized 
nurse with a formal background in mental health) observed at least 
10% of the sessions and completed an adherence form for each 
SH+ session. 
ETAU was provided to the control group and consisted of rou-
tinely delivered social support and/or care according to local regu-
lations. Additionally, participants in the ETAU arm received base-
line and follow-up assessments according to the study schedule 
(around 2 and 6 months after randomization, respectively), infor-
mation about freely available health and social services, and links 
to community networks providing support to refugees and asylum 
seekers.
An ethics advisory board, consisting of experts giving advice on 
any ethical issues related to the trial, supervised this study. 
Outcomes
The primary outcome was the presence of current mental dis-
orders at the 6-month follow-up measured using the MINI, which 
was also administered as a screener, and after the intervention [22]. 
Validation and reliability studies have been conducted comparing 
the MINI to the Structured Clinical Interview for DSM-III-R [27] 
and the Composite International Diagnostic Interview, i.e., a 
structured interview developed by the WHO [28]. 
All other measures were secondary outcomes assessed at after 
the intervention and at the 6-month follow-up. Psychological dis-
tress was measured using the GHQ-12 questionnaire, asking 
whether the respondent has experienced a particular symptom or 
behavior recently [21]. Each item is rated on a 4-point Likert scale 
and gives a total score of 12 points based on the GHQ version and 
on the selected scoring methods. PTSD symptoms were assessed 
with the PTSD Checklist for DSM-5 (PCL-5) [29, 30], a 20-item 
questionnaire that measures PTSD symptom severity globally 
(score 0–80) and by cluster (intrusions, avoidance, negative chang-
es in thoughts and mood, and changes in arousal). We measured 
depression symptoms with the Patient Health Questionnaire, 
9-item version (PHQ-9) [31], a 4-point scale measure (score 0 to 
27). Personally identified problems were examined with the Psy-
chological Outcome Profiles instrument (PSYCHLOPS) [32], ask-
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ing participants to describe 2 problems from their own perspective 
and rate the problem severity on a 6-point scale (range 0–18). Func-
tional impairment and subjective wellbeing were assessed with the 
WHO Disability Assessment Schedule 2.0 (WHODAS) [33] and 
the WHO-5 Wellbeing Index (WHO-5) [34], respectively. We ad-
ministered the 12-item version of the WHODAS, which uses a 
5-point scale (score 12–60). The WHO-5 contains 5 questions us-
ing a 6-point scale (score 0–25). For evaluation of general health, 
we administered the EQ-5D-3L questionnaire, which is a brief self-
report measure consisting of 5 dimensions (mobility, self-care, usu-
al activities, pain/discomfort, and anxiety/depression) [35]. Trau-
matic/adverse life events and daily and environmental stressors 
were collected with the Harvard Trauma Questionnaire (HTQ)-
Part A [36] and the 17-item Checklist for Post-Migration Living 
Difficulties (PMLD) [37]. HTQ-Part A asks for lifetime traumatic 
life events. The PMLD instead asks respondents to rate their expe-
rience of the problems, during the last 12 months, on a 5-point scale 
(from “was not a problem” to “very serious problem”). 
Assessments were conducted as face-to-face interviews or re-
motely by telephone or secure online audio/video communication 
for reasons of feasibility related to the SARS-CoV2 pandemic. Ad-
verse events reported spontaneously by the participants or ob-
served by the research staff were recorded, reviewed by the ethics 
advisory board in regular meetings, and reported to the WHO Eth-
ics Committee in midterm reports.
Researchers involved in screening, baseline, and follow-up as-
sessments received specific 2-h training sessions for administering 
the MINI and the rating scales for measuring secondary outcomes 
by expert trainers based at the University of Verona.
In addition, we assessed secondary outcomes at the 12-month 
follow-up, as well as cost-effectiveness indicators. The results from 
these assessments will be presented elsewhere. 
Statistical Analysis
We predicted a frequency rate of current mental disorders of 
25% at 6 months in this population. We hypothesized that the pro-
vision of SH+ would show a clinically significant advantage by pro-
ducing a between-groups absolute difference of 10% [19]. With 
these figures, in order to achieve at least 80% power for a 0.05 
level of significance in a χ2 test for equality of proportions of people 
diagnosed with current mental disorders at 6 months, a sample size 
of 500 participants (250 in each group) was needed. 
Descriptive statistics (mean and SD for continuous variables 
and absolute numbers and percentages for categorical variables) 
were calculated on sociodemographic, premigration, migration, 
and postmigration variables at baseline. Balance between treat-
ment groups was checked by calculating standardized mean differ-
ences (SMD) using values of 0.1 and –0.1 as thresholds for imbal-
ance [38, 39]. 
We followed an intention-to-treat (ITT) approach for the anal-
ysis of primary and secondary outcomes. The ITT population con-
sisted of all participants randomly assigned to the competing in-
tervention strategies, and with data on the baseline assessment 
available, irrespectively of the number of SH+ sessions received. 
To check the robustness of results, the primary outcome was ad-
ditionally analyzed using a per protocol (PP) approach for confir-
matory purposes only, by including only those participants who 
completed at least 3 SH+ sessions. 
The primary outcome was compared between the 2 groups 
through a χ2 test (primary analysis); the Cramer V was also calcu-
lated, together with a RR and its 95% CI (Cramer V details are in 
the online suppl. Appendix; for all online suppl. material, see www.
karger.com/doi/10.1159/000517504). Additionally, a multivariate 
analysis (secondary analysis) was performed through a Poisson re-
gression model, with a robust error variance, to explore the poten-
tial confounding effect of prognostic factors, and the interactions 
with treatment, controlling for variables unbalanced at baseline. 
We also performed a mixed analysis of covariance (ANCOVA) 
controlling for baseline scores, with robust standard errors and 
distinct variances for postintervention and the 6-month follow-up. 
In addition to mixed models, a last observation carried forward 
(LOCF) approach was used to account for missing observations at 
6 months. Standardized coefficients, together with their SEs, were 
also calculated with the Stata “stdBeta” command [40]. We tested 
the null hypothesis of the intervention having no effect on any out-
comes versus the alternative hypothesis of the intervention having 
an effect on at least 1 outcome by performing a seemingly unre-
lated regression (SUR) [41] equations model, in its modification to 
allow for unbalanced data as proposed by Baum and Schaffer [42], 
through the Stata “suregub” command. In particular, SURs were 
performed for each time point, controlling for baseline values. For 
each questionnaire, in case of missing items, we used the corrected 
item mean substitution method (i.e., the item mean across par-
ticipants weighted by the subject’s mean of completed items) [43], 
using information from subjects belonging to the same treatment 
arm for the same follow-up time, through the Stata “hotvalue” 
command [44]. The substitution was only performed for observa-
tions having <50% missing items and if it resulted in admissible 
values in all cases. As a sensitivity analysis, we reran our models 
without any data imputation.
Possible interactions between treatment and specific variables 
(recruiting center, country of origin, gender, age, years of educa-
tion, and length of stay in the hosting country) were evaluated. In 
particular, in the case of continuous outcomes, SURs for unbal-
anced data on all outcomes was performed, with their value at 
baseline, treatment status, all potential moderators, and their in-
teractions with treatment status as predictors. A global test on all 
interaction terms was implemented and, in case of statistical sig-
nificance, the same test was performed for each scale. Finally, for 
scales meeting the statistical significance threshold, single regres-
sions were considered.
As for binary outcomes, to avoid the issue of poor performance 
of the model in case of solutions near the boundary described in 
Zhu et al. [45], Poisson regression models with robust standard 
errors, having the variable “intervention allocation,” each variable 
separately, and its interaction with treatment as regressors, were 
performed using the Bonferroni correction to take multiple testing 
into account. Originally, further analyses stratifying by method of 
assessment (face-to-face vs. telephone or secure online audio/vid-
eo communication) were planned. However, due to the SARS-
CoV2 pandemic, these analyses were not performed, as most fol-
low-up assessments were conducted remotely. 
For each secondary outcome, we performed multivariate anal-
yses to take confounding factors into account, again including the 
baseline value as a covariate. Finally, lost-to-follow-up was com-
pared between the 2 groups using a χ2 or a Fisher exact test, as ap-
propriate. We also conducted 2 post hoc analyses, i.e., 1 analysis 
using the LOCF approach for the MINI at the 6-month follow-up 
by imputing missing values using information after the interven-
tion and 1 analysis considering deterioration of psychological 
SH+ for Preventing Mental Disorders in 
Refugees and Asylum Seekers
5Psychother Psychosom
DOI: 10.1159/000517504
symptoms (PHQ-9, PCL-5, and WHODAS) after the intervention. 
All analyses were performed using Stata/SE, release 16.1 [46]. A 
statistical analysis plan was developed and signed before data anal-
ysis. 
Results
After screening of 1,475 potentially eligible partici-
pants, 1,016 were excluded. A total of 505 participants 
were excluded because the level of distress was lower than 
the established cut-off, 461 participants were excluded 
because of a positive MINI, and 50 participants were ex-
cluded for other reasons (Fig. 1). 
This left 459 individuals who met the inclusion crite-
ria, consented to be randomized by signing a written in-
formed consent form, and were allocated to either SH+ 
(230) or ETAU (229). We could not assess 112 individuals 
at post-intervention with the M.I.N.I. (24%), of which 
59/230 in SH+ group and 53/229 in ETAU group, and 156 
individuals at 6-month follow-up (34%), of which 84/230 
in SH+ group and 72/229 in ETAU. Participants were lost 
to 6-month follow-up because they refused to participate 
(69), were not reachable and/or moved to other locations 
(40), or were not available due to other personal priorities 
(i.e., working, housing, other) (47). The distribution of 
participants lost to follow-up was similar between the 
study groups (Table 1). 
Selected sociodemographic characteristics of the in-
cluded participants are shown in Table 2 (the full list is 
presented in the online suppl. Appendix, Table 1). 
The mean participant age was 33 years (SD = 11) in 
the SH+ group and 32 years (SD = 10) in the ETAU 
group. Approximately 7 out of every 10 participants 
were male. For about 40% primary school was the high-
est level of education, while 20% had received academ-
ic education, with 10 years of education on average. 
About 28% of the participants came from Syria, 25% 
Analyses of primary 
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Fig. 1. CONSORT flow diagram.
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Table 1. Summary statistics of the results for primary and secondary outcomes at each time point
Binary outcomes ETAU SH+ Cramer V p value
Frequency of current mental disorders, n (%)
Baseline 0/229 (0) 0/230 (0) – –
Postintervention 33/176 (18.75) 16/171 (9.36) 0.135 0.012 –
6 months (primary outcome) 19/157 (12.10) 17/146 (11.64) 0.007 0.902 –
Lost to follow-up, n (%)
Postintervention 53/229 (23.14) 59/230 (25.65) 0.029 0.532 –
6 months 72/229 (31.44) 84/230 (36.52) 0.054 0.251 –
Continuous outcomes Coefficient p value Std Coef (SE)
GHQ score (0–12)        
Screening (n = 459) 5.507 (2.447) 5.619 (2.185) – – –
Postintervention (n = 344) 4.154 (3.383) 3.071 (2.991) –1.014 0.002 –0.157 (0.051)
Postintervention (mixed model) –1.017 0.002 –0.160 (0.052)
6-month LOCF (n = 368) 3.118 (3.204) 2.973 (3.068) –0.110 0.729 –0.018 (0.051)
6 months (n = 294; mixed model) 2.876 (3.090) 2.966 (3.073) 0.113 0.747 0.018 (0.055)
PCL5 score (0–80)      
Baseline (n = 459) 22.765 (16.239) 24.692 (16.352) – – –
Postintervention (n = 341) 20.930 (16.966) 19.223 (15.820) –2.556 0.108 –0.078 (0.048)
Postintervention (mixed model) –2.261 0.149 –0.070 (0.049)
6-month LOCF (n = 365) 18.053 (15.496) 17.533 (15.958) –1.503 0.297 –0.048 (0.046)
6 months (n = 288; mixed model) 16.794 (15.298) 17.062 (16.096) –1.406 0.382 –0.044 (0.050)
PHQ9 score (0–27)        
Baseline (n = 459) 8.384 (5.546) 8.478 (5.816) – – –
Postintervention (n = 342) 7.595 (5.817) 6.098 (5.408) –1.418 0.013 –0.125 (0.050)
Postintervention (mixed model) –1.358 0.016 –0.120 (0.050)
6-month LOCF (n = 365) 6.925 (5.779) 6.124 (5.710) –0.761 0.184 –0.066 (0.050)
6 months (n = 289; mixed model) 6.493 (5.747) 6.063 (5.571) –0.570 0.365 –0.050 (0.056)
WHO-5 (0–100)        
Baseline (n = 459) 47.354 (24.984) 46.723 (23.625) – –
Postintervention (n = 343) 47.977 (25.315) 56.357 (24.977) 8.882 0.001 0.175 (0.051)
Postintervention (mixed model) 8.377 0.001 0.162 (0.050)
6-month LOCF (n = 366) 48.834 (26.251) 57.855 (25.146) 9.526 <0.001 0.183 (0.050)
6 months (n = 290; mixed model) 50.693 (26.401) 57.229 (25.949) 8.425 0.004 0.163 (0.056)
WHODAS (0–1)        
Baseline (n = 459) 0.152 (0.144) 0.148 (0.141) – – –
Postintervention (n = 337) 0.113 (0.145) 0.115 (0.149) 0.001 0.939 0.004 (0.049)
Postintervention (mixed model) 0.003 0.858 0.009 (0.053)
6-month LOCF (n = 364) 0.101 (0.133) 0.093 (0.110) –0.009 0.452 –0.036 (0.047)
6 months (n = 292; mixed model) 0.092 (0.127) 0.094 (0.112) –0.002 0.871 –0.008 (0.047)
PSYCHLOPS score (0–20)
Baseline (n = 432) 13.925 (4.396) 14.097 (4.013) – – –
Postintervention (n = 325) 12.882 (4.903) 11.128 (5.412) –1.771 0.001 –0.172 (0.052)
Postintervention (mixed model) –1.697 0.001 –0.166 (0.052)
6-month LOCF (n = 353) 11.312 (5.122) 10.853 (5.253) –0.577 0.274 –0.056 (0.051)
6 months (n = 278; mixed model) 11.005 (4.981) 11.188 (5.068) –0.180 0.753 –0.018 (0.056)
PMLD (0–68)
Baseline not measured – – – – –
Postintervention (n = 342) 25.587 (12.846) 24.174 (12.199) – – –
6 months (n = 289) 20.490 (11.510) 20.607 (11.747) 0.470 0.660 0.020 (0.046)
EQ-5D
Baseline (n = 455) 0.706 (0.276) 0.716 (0.280) – – –
Postintervention not measured – – – – –
6 months (n = 287) 0.751 (0.296) 0.767 (0.274) 0.037 0.219 0.067 (0.054)
Values in bold indicate statistically significant differences.
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came from Nigeria, and 18% came from Iraq, followed 
by Afghanistan, Pakistan, and other bordering coun-
tries. The travel route for moving to Western Europe 
was through the Balkans for 28% of the participants in 
the SH+ group and 34% of those in the ETAU group, 
followed by the African route, the Eastern route, and 
other travel routes. About 30% of the participants expe-
rienced detention during their transition to Europe. 
The 2 groups were similar with regard to most sociode-
mographic characteristics and baseline scores on out-
comes, with the exception of the following variables: 
literacy, having distant relatives in the country of ori-
gin, detention duration, legal status conditions, and 
number of siblings. We added these variables in planned 
regression analyses accounting for imbalance between 
groups, without identifying relevant differences with 
respect to our main analyses on both primary and sec-
ondary outcomes (online suppl. Appendix, Table 4).
Assessment of more than 10% of SH+ sessions showed 
near-perfect fidelity. We only identified small mistakes 
consisting of longer breaks (10–15 min) in restarting the 
audio and taking more time for group discussion than al-
lotted in the manual. Based on information collected at 
each site, the total supervision time required for all 5 ses-
sions of an SH+ group was 2 h on average per group. 
Differences between study conditions on primary and 
secondary outcomes are reported in Table 1. 
SH+ led to a significant reduction in the frequency of 
any current mental disorders as measured with the MINI 
after the intervention (within 2 weeks from the last SH+ 
session) (Cramer V = 0.135, p = 0.012, RR = 0.499; 95% 
CI 0.285–0.873), but not at the 6-month follow-up (pri-
mary outcome: Cramer V = 0.007, p = 0.902, RR = 0.962; 
95% CI 0.521–1.778). The majority of detected mental 
disorders after the intervention were major depressive 
disorders (9 out of 171 participants in the SH+ group and 
20 out of 176 participants in the ETAU group), anxiety 
disorders (4 out of 171 participants in the SH+ group and 
7 out of 176 participants in the ETAU group), and PTSD 
(2 out of 171 participants in the SH+ group and 7 out of 
176 participants in the ETAU group). At the 6-month fol-
low-up, the majority of the detected mental disorders 
were major depressive disorders (12 out of 146 partici-
pants in the SH+ group and 16 out of 157 participants in 
the ETAU group), anxiety disorders (2 out of 146 par-
ticipants in the SH+ group and 3 out of 157 participants 
Table 2. Demographic characteristics
Variable ETAU SH+ Difference (SE) SMD
Mean age (SD), years 31.537 (9.505) 32.961 (10.779) 1.424 (0.949) 0.099
Female gender 30.13 (69/229) 28.26 (65/230) –0.019 (0.043) –0.029
Mean education (SD), years 10.157 (5.451) 10.452 (4.890) 0.295 (0.497) 0.040
Type of education
Illiterate 11.50 (26/226) 5.73 (13/227) –0.058 (0.026) –0.146
Primary school 40.71 (92/226) 44.93 (102/227) 0.042 (0.047) 0.060
High school 27.88 (63/226) 27.75 (63/227) –0.001 (0.042) –0.002
University 19.91 (45/226) 20.70 (47/227) 0.008 (0.038) 0.014
Mean relatives (SD), n 1.655 (2.413) 1.409 (1.978) –0.246 (0.206) –0.079
Mean children (SD), n 1.369 (2.426) 1.348 (1.798) –0.021 (0.200) –0.007
Country of origin
Afghanistan 14.41 (33/229) 14.35 (33/230) –0.001 (0.033) –0.001
Iraq 18.78 (43/229) 17.39 (40/230) –0.014 (0.036) –0.025
Nigeria 24.02 (55/229) 25.65 (59/230) 0.016 (0.040) 0.027
Pakistan 9.61 (22/229) 8.26 (19/230) –0.013 (0.027) –0.033
Syria 28.38 (65/229) 28.26 (65/230) –0.001 (0.042) –0.002
Other country 4.80 (11/229) 6.09 (14/230) 0.013 (0.021) 0.040
Travel route
Balkan 34.50 (79/229) 28.26 (65/230) –0.062 (0.043) –0.095
Eastern 19.65 (45/229) 22.17 (51/230) 0.025 (0.038) 0.044
African 26.64 (61/229) 27.83 (64/230) 0.012 (0.042) 0.019
Other 18.34 (42/229) 20.43 (47/230) 0.021 (0.037) 0.037
Detention during transition 29.46 (66/224) 31.70 (71/224) 0.022 (0.044) 0.034
Values in bold indicate an imbalance at baseline.
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in the ETAU group), and PTSD (3 out of 146 participants 
in the SH+ group and 3 out of 157 participants in the 
ETAU group). Figure 2 is a graphical representation of 
the trend over time in the frequency of current mental 
disorders in each of the 2 groups and of their difference.
SH+, compared with ETAU, was also associated with 
larger improvements after the intervention for the sec-
ondary outcomes of psychological distress as measured 
with the GHQ-12 (standardized coefficient [Std Coef] = 
–0.157, SE = 0.051, p = 0.002), depression symptoms as 
measured with the PHQ-9 (Std Coef = –0.125, SE = 0.050, 
p = 0.013), wellbeing as measured with the WHO-5 (Std 
Coef = 0.175, SE = 0.051, p = 0.001), and perceived prob-
lems as measured with the PSYCHLOPS (Std Coef = 
–0.172, SE = 0.052, p = 0.001). Such results were con-
firmed by the global statistical significance of the inter-
vention on all outcomes by performing SURs (p = 0.001). 
At 6 months, we detected a statistically significant differ-
ence in favor of SH+ on the WHO-5 (Std Coef = 0.187, 
SE = 0.050, p ≤ 0.001), while the other secondary outcome 
differences were not statistically significant. Results from 
SURs showed evidence of a global effect of treatment on 
secondary outcomes (p = 0.005) also at the 6-month fol-
low-up. Results from the ANCOVA controlling for base-
line scores were fully consistent with analyses using the 
LOCF approach (Table 1). 
The ITT analysis results were confirmed in the PP 
analysis (online suppl. Appendix, Table 2). Secondary 
analyses of continuous outcomes conducted without any 
imputations of missing values did not identify any rele-
vant difference with respect to the main analyses (online 
suppl. Appendix, Table 3). 
We then proceeded to investigate the possible hetero-
geneity of the effect of treatment on outcomes by testing 
for interactions between intervention allocation and po-
tential moderators. None of the interactions reached the 
statistical significance threshold for binary outcomes after 
application of the Bonferroni correction. By performing 
SURs on postintervention secondary outcomes, a global 
test on all interactions of the variable “intervention alloca-
tion,” with center and the potential moderators on all re-
gressions, turned out to be not statistically significant (p = 
0.581). The same test performed at the 6-month follow-up 
revealed interactions to be statistically significant (p = 
0.025). We then conducted single regressions and found a 
global statistical significance of all interactions only in the 
regression having WHODAS as an outcome (p < 0.001). 
Thus, we performed simple models controlling for WHO-
DAS at baseline and with the variable “intervention allo-
cation”, each separate variable, and their interaction as re-
gressors. Only length of stay in the hosting country (p = 
0.022) and years of education (p = 0.042) emerged as sta-
tistically significant moderators. As shown in online sup-
plementary Appendix, Figure 1, a significant protective 
effect of SH+ on the WHODAS score at 6 months emerged 
for those who had already been in the host country for 6 
years or longer. Post hoc analyses using the LOCF ap-
proach for the MINI, and considering deterioration of 
psychological symptoms as an additional outcome, did 
not show any differences between groups (online suppl. 
Appendix, Tables 5, 6). With regard to safety consider-
ations, the ethics advisory board responded to 8 adverse 
events that were equally distributed between groups (5 in 
ETAU and 3 in SH+), and none was evaluated to be re-
lated to the study/intervention participation.
Cramer’s 
V = 0.135











































Fig. 2. Trend in the frequency of any men-
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This is the first study in refugees and asylum seekers 
resettled in Western Europe that examines the effects of 
a preventive intervention on the development of mental 
disorders. It is likely the largest intervention study ever 
conducted in this population group in high-income 
countries. Though we did not find a preventive effect of 
SH+ on the presence of current mental disorders at the 
6-month follow-up, which was our primary outcome, we 
found a significant difference in favor of SH+ in reducing 
the frequency of current mental disorders immediately 
after the intervention. 
Several reasons may explain the loss of effect over time, 
in particular the short duration of the intervention and a 
likely reduction of practice or application of the tech-
niques after the group ended. A lack of participant blind-
ness to the allocated interventions might be another rea-
son, as knowledge of being allocated to the “enhanced 
intervention as usual” arm might have disappointed par-
ticipants, leading to worse mental health conditions in the 
control group after the intervention. At 6 months, how-
ever, the control group participants could have moved 
beyond an initial disappointment, reversing to the same 
level of mental health problems as the intervention group 
[47]. However, analysis of secondary outcomes did not 
suggest any worsening in the control group mental health 
conditions, so a nocebo effect related to control group al-
location seems unlikely. A third reason might be related 
to the nonspecific intervention ingredients of SH+, which 
being transdiagnostic and based on the ACT might have 
generated a significant effect after the intervention, pro-
moting flexibility and generic psychological skills that can 
be enhanced in any domain of life but not lasting over 
longer periods.
Interestingly, a decreased intervention effect over time 
was similarly observed in the SH+ treatment trial con-
ducted in Uganda, which involved a larger group of par-
ticipants [18]. More generally, reviews on the effective-
ness of psychosocial interventions in vulnerable popula-
tions have found that the beneficial effects of interventions 
on PTSD, depression, and anxiety symptoms were re-
duced at follow-up [11, 13]. A recent systematic review of 
17 RCTs involving 1,108 adult refugees confirmed a 
strong beneficial effect of psychological interventions in 
reducing PTSD and depression immediately after the in-
tervention; this effect was reduced, but still statistically 
significant, at follow-up [8]. Compared to SH+, these in-
terventions generally provided a larger intervention 
“dose,” for example because they were delivered as indi-
vidual interventions or because the number of sessions 
was substantially greater. The length of follow-up was up 
to 6 months in the majority of the included studies [8]. In 
addition, there was a high heterogeneity across the in-
cluded studies, indicating that there are moderators and 
mediators that need to be investigated in further analyses. 
Finally, meta-analyses from the available systematic re-
views included very small studies, raising concerns re-
garding methodological standards and quality [48–50]. 
Little knowledge exists of whether these drops in effect 
sizes are due to intervention-related processes (e.g., a re-
turn to previous emotional/behavioral patterns), context-
related variables (e.g., new or continued adversities expe-
rienced in the host countries, associated with renewed 
psychological distress), research-related variables (e.g., 
halo effect), or the impact that increased adversity may 
have on the effect of interventions over time. Likely, sec-
ondary analyses of the present study, and individual-par-
ticipant data reanalyses of the whole body of randomized 
evidence on the efficacy of psychological interventions in 
vulnerable populations, will be able to ascertain which 
factors may contribute to maintenance versus loss of the 
effect over time.
For SH+, it will be important to explore whether boost-
er sessions after the delivery of the group intervention, 
administered face-to-face or through online devices [51], 
might assist in maintaining its benefits over time. Nota-
bly, booster sessions for SH+ are possible, using the pub-
lication of the SH+ illustrated book Doing What Matters 
in Times of Stress: An Illustrated Guide [25]. 
We note several limitations of our study. First, al-
though this is the largest study in this population in high-
income countries, we were only able to get close to, but 
did not reach, the planned sample size. Several potential 
factors may have contributed to the smaller sample size. 
As the included participants did not have a mental disor-
der, they may not have perceived their psychological well-
being as a priority. Reported priorities included uncer-
tainty about the refugee application, housing, unstable 
working conditions, and plans to move to another coun-
try. These factors may have limited engagement and 
availability to participate. Moreover, we identified a rela-
tively large proportion of individuals with a diagnosis of 
mental disorder who were advised to seek appropriate 
care according to a predefined protocol and were exclud-
ed from participation. We note, however, that the system-
atic exclusion of participants with a mental disorder at 
baseline is a key strength of our study, as compared with 
previous studies evaluating psychological interventions 
on severely distressed participants who are more likely to 
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respond to the intervention or to attend the sessions be-
cause they prioritize the intervention more [52, 53]. These 
studies did not exclude participants with mental disor-
ders at baseline, making it impossible to calculate the fre-
quency of new cases of mental disorders at follow-up [54, 
55]. Despite these challenges in reaching the target sam-
ple size, we were able to detect a statistically and clini-
cally significant difference after treatment, thus indicat-
ing sufficient statistical power for this secondary analysis. 
Second, a double-blind design was not feasible. How-
ever, outcome assessors were masked, i.e., they were not 
involved in any trial phase that might break their blind-
ness [56, 57]. For that reason, both participants and asses-
sors were instructed not to mention any interventions re-
ceived during the study.
A third limitation is related to the heterogeneity of the 
included population groups. The choice of involving people 
from multiple backgrounds was justified by the need to gen-
erate an evidence base for an intervention that has the po-
tential for large-scale uptake across migrant populations. 
Finally, a substantial proportion of participants was 
lost to follow-up (more than 20% after the intervention 
and more than 30% at the 6-month follow-up). We note, 
however, that the number of people lost to follow-up is in 
line with the expectations listed in the study protocol [19] 
and similar to those reported in other psychological in-
tervention studies [13, 18].
Given the characteristics of SH+, i.e., delivery by brief-
ly trained nonspecialist peers, its ease of implementation, 
the large group format, its short-term efficacy in prevent-
ing the development of mental disorders, its efficacy in 
ameliorating psychological distress in different popula-
tions, and the lack of adverse effects associated with its 
delivery, it might be considered as a public health strategy 
for healthcare agencies and nongovernmental organiza-
tions implementing migrant reception programs. Further 
research should be conducted to replicate results imme-
diately after intervention and to explore the potential ef-
fects of booster SH+ sessions to reinforce the beneficial 
effects even in the long term. 
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